Khiron Life Sciences closes overnight brokered offering including full exercise of over-allotment option

On June 10, 2022, Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) (Frankfurt: A2JMZC) closed its previously announced underwritten overnight public offering of units of the company, including the exercise in full of the over-allotment option.

A total of 30,705,000 units were sold for aggregate gross proceeds of $4,605,750. The offering was completed by a syndicate of underwriters led by Canaccord Genuity Corp., including ATB Capital Markets Inc. and Leede Jones Gable Inc.

Khiron is a leading vertically integrated international medical cannabis corporation with core operations in Latin America and Europe. The company has a sales presence in Colombia, Peru, Germany, the United Kingdom and Brazil and is positioned to commence sales in Mexico.

Gowling WLG was counsel to Khiron in this transaction with a team that included Peter Simeon, Jacob Cawker and Ashley Andaya.